BioArctic royalty revenue climbs following Leqembi sales growth
BioArctic’s royalty income rose by 74 percent year-on-year to 203.8 million SEK as Leqembi sales reached 32.2 billion yen in the third quarter of 2026.
Global sales of the Alzheimer’s disease drug Leqembi totaled 32.2 billion yen during the third quarter of 2026. The figures were disclosed by BioArctic’s partner Eisai in conjunction with the third-quarter report from Biogen.
The sales performance resulted in royalty payments to BioArctic amounting to 203.8 million SEK. This figure represents an approximately 74 percent increase compared to the royalty income recorded in the third quarter of 2025, signaling continued growth for the treatment.
BioArctic is scheduled to release its comprehensive financial report for the third quarter of 2026 on November 25.